Prostate News Archive
17-Apr-2007
Measuring Calcium Intake Can Help To Identify Osteoporosis In Men With Prostate Cancer (Medical News Today)
Measuring a man's daily calcium intake is an effective way of identifying prostate cancer patients with a higher than average risk of osteoporosis, according to the April issue of the urology journal BJU International.Researchers from the Autonoma University School of Medicine, Barcelona, Spain, looked at a cross-section of 372 men with prostate cancer. [click link for full article] New imaging technique helps measure effectiveness of prostate cancer treatment (ANI via Yahoo! India News)
Washington, Apr 16 (ANI): Boffins have developed an imaging technique called a 'functional diffusion map' that can measure the effectiveness of treatment for prostate cancer that has spread to the bones. The imaging technique, called a functional diffusion map, uses a magnetic resonance imaging scan and special software to track the diffusion, or movement, of water through the cells. ... Prostate Cancer Progression In The Presence Of Undetectable Or Low Serum Prostate-Specific Antigen Level (Medical News Today)
UroToday.com- Patients treated with definitive therapy for prostate cancer (CaP) are reassured that a low or undetectable PSA means the absence of metastatic disease. However, exceptions to this can occur, as documented in a study from M.D. Anderson Cancer Center that appears in the online edition of Cancer. [click link for full article] Prostate-Specific Antigen (PSA) And PSA Velocity For Prostate Cancer Detection In Men Aged Less Than 50 Years (Medical News Today)
UroToday.com- Both BPH and prostate cancer CaP can contribute to serum PSA levels. Younger men have less of a BPH contribution to overall PSA production and therefore, lowering PSA level thresholds in men aged 14,000 patients with CaP. From this, 904 men age 50 years and no cancer, the median PSA and PSA velocity (PSAV) were 5.1ng/ml and 0.25ng/ml/year, respectively vs. 6.3ng/ml and 1. [click ... Prostate Cancer Risk Among Users Of Finasteride And Alpha-Blockers A Population Based Case Control Study (Medical News Today)
UroToday.com- Current medical management for BPH includes alpha-blockers and 5 reductase inhibitors. In the prostate Cancer Prevention Trial, finasteride, a 5 reductase inhibitor was shown to decrease the risk of developing prostate cancer by 24.8% over 7.2 years. Dr. [click link for full article]
Back to Prostate News Archive
